Identification of the molecular basis of doxorubicin-induced cardiotoxicity

被引：1411

作者：

Zhang, Sui ^{[1
]}

Liu, Xiaobing ^{[2
,3
]}

Bawa-Khalfe, Tasneem ^{[1
]}

Lu, Long-Sheng ^{[2
]}

Lyu, Yi Lisa ^{[4
]}

Liu, Leroy F. ^{[4
]}

Yeh, Edward T. H. ^{[1
,2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA

[2] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA

[3] Shanghai Jiao Tong Univ, Dept Vasc Surg, Peoples Hosp 9, Sch Med, Shanghai 200030, Peoples R China

[4] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA

来源：

NATURE MEDICINE | 2012年 / 18卷 / 11期

基金：

美国国家卫生研究院;

关键词：

TOPOISOMERASE-II-BETA; INDUCED CARDIOMYOPATHY; HEART; GENE; TRANSCRIPTION; EXPRESSION; PREVENTION; PGC-1-BETA; APOPTOSIS; ADULT;

D O I：

10.1038/nm.2919

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen species (ROS). Here we show that cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-II beta) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation. Furthermore, cardiomyocyte-specific deletion of Top2b protects mice from the development of doxorubicin-induced progressive heart failure, suggesting that doxorubicin-induced cardiotoxicity is mediated by topoisomerase-II beta in cardiomyocytes.

引用

页码：1639 / +

页数：7

共 50 条

[1] Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang
Xiaobing Liu
Tasneem Bawa-Khalfe
Long-Sheng Lu
Yi Lisa Lyu
Leroy F Liu
Edward T H Yeh
Nature Medicine, 2012, 18 : 1639 - 1642
[2] DOXORUBICIN-INDUCED CARDIOTOXICITY
SAMUEL, L
POSTGRADUATE MEDICAL JOURNAL, 1995, 71 (835) : 318 - 318
[3] DOXORUBICIN-INDUCED CARDIOTOXICITY
SILBER, JH
BARBER, G
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20): : 1359 - 1360
[4] Modification of doxorubicin-induced cardiotoxicity
Hadi, N. R.
Ali, S. J.
Mohammad, B., I
9TH CONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS - EACPT, 2009, : 77 - +
[5] Identification of autophagy-related signatures in doxorubicin-induced cardiotoxicity
Wu, Haiyan
Chen, Haoqiang
Ding, Xiaoxue
Kuang, Xiaohui
Pang, Mingjie
Liu, Suijuan
Zhang, Yan
Wang, Qian
Li, Kunzhi
Zhang, Hong
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2024, 491
[6] Molecular insights into the pathophysiology of doxorubicin-induced cardiotoxicity: a graphical representation
Nonhlakanipho F. Sangweni
Kwazi Gabuza
Barbara Huisamen
Lawrence Mabasa
Derick van Vuuren
Rabia Johnson
Archives of Toxicology, 2022, 96 : 1541 - 1550
[7] Molecular Mechanisms and Therapeutic Targeting of Ferroptosis in Doxorubicin-Induced Cardiotoxicity
Wu, Lin
Zhang, Yingmei
Wang, Guizhen
Ren, Jun
JACC-BASIC TO TRANSLATIONAL SCIENCE, 2024, 9 (06): : 811 - 826
[8] Molecular insights into the pathophysiology of doxorubicin-induced cardiotoxicity: a graphical representation
Sangweni, Nonhlakanipho F.
Gabuza, Kwazi
Huisamen, Barbara
Mabasa, Lawrence
van Vuuren, Derick
Johnson, Rabia
ARCHIVES OF TOXICOLOGY, 2022, 96 (06) : 1541 - 1550
[9] CLINICAL PRESENTATIONS OF DOXORUBICIN-INDUCED CARDIOTOXICITY
SAOUR, J
KING FAISAL SPECIALIST HOSPITAL MEDICAL JOURNAL, 1984, 4 (03): : 257 - 261
[10] Polyphenols, autophagy and doxorubicin-induced cardiotoxicity
Shabalala, S.
Muller, C. J. F.
Louw, J.
Johnson, R.
LIFE SCIENCES, 2017, 180 : 160 - 170

← 1 2 3 4 5 →